PharmaCyte Biotech Valuation
| PMCB Stock | USD 1.67 0.01 0.60% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. PharmaCyte Biotech holds a recent Real Value of $1.39 per share. The prevailing price of the company is $1.67. Our model determines the value of PharmaCyte Biotech from analyzing the company fundamentals such as Shares Outstanding of 6.87 M, return on equity of 0.43, and Shares Owned By Institutions of 11.44 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that PharmaCyte Biotech's price fluctuation is dangerous at this time. Calculation of the real value of PharmaCyte Biotech is based on 3 months time horizon. Increasing PharmaCyte Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since PharmaCyte Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of PharmaCyte Stock. However, PharmaCyte Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.67 | Real 1.39 | Hype 1.67 | Naive 1.54 |
The real value of PharmaCyte Stock, also known as its intrinsic value, is the underlying worth of PharmaCyte Biotech Company, which is reflected in its stock price. It is based on PharmaCyte Biotech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of PharmaCyte Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of PharmaCyte Biotech helps investors to forecast how PharmaCyte stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of PharmaCyte Biotech more accurately as focusing exclusively on PharmaCyte Biotech's fundamentals will not take into account other important factors: PharmaCyte Biotech Total Value Analysis
PharmaCyte Biotech is at this time forecasted to have valuation of (5.22 M) with market capitalization of 11.54 M, debt of 20.39 M, and cash on hands of 82.23 M. The negative valuation of PharmaCyte Biotech may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the PharmaCyte Biotech fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(5.22 M) | 11.54 M | 20.39 M | 82.23 M |
PharmaCyte Biotech Asset Utilization
One of the ways to look at asset utilization of PharmaCyte is to check how much profit was generated for every dollar of assets it reports. PharmaCyte Biotech holds a negative application of assets of -0.0505 pct., losing $5.05E-4 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of PharmaCyte Biotech shows how discouraging it operates for each dollar spent on its assets.PharmaCyte Biotech Ownership Allocation
The market capitalization of PharmaCyte Biotech is $11.54 Million. PharmaCyte Biotech holds 10.69 pct. of its outstanding shares held by insiders and 11.44 pct. owned by third-party entities. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the company is less than the current market value, you may not be able generate positive returns on investment in the long run.PharmaCyte Biotech Profitability Analysis
Net Income was 333.76 K with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates PharmaCyte Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in PharmaCyte Biotech and how it compares across the competition.
About PharmaCyte Biotech Valuation
The stock valuation mechanism determines PharmaCyte Biotech's current worth on a weekly basis. Our valuation model uses a comparative analysis of PharmaCyte Biotech. We calculate exposure to PharmaCyte Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of PharmaCyte Biotech's related companies.PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. Pharmacyte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.
PharmaCyte Biotech Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 9.6 M |
Complementary Tools for PharmaCyte Stock analysis
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |